TPTX Stock Overview
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Turning Point Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$76.01 |
| 52 Week High | US$82.20 |
| 52 Week Low | US$23.77 |
| Beta | -0.19 |
| 1 Month Change | 1.58% |
| 3 Month Change | 114.96% |
| 1 Year Change | 18.90% |
| 3 Year Change | 45.39% |
| 5 Year Change | n/a |
| Change since IPO | 163.01% |
Recent News & Updates
Recent updates
Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report
Jul 21We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth
Mar 23
Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth
Dec 06The Take On Turning Point Therapeutics
Dec 03Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts
Aug 15Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business
Aug 04Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer
Jun 17Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 08Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?
Feb 26Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study
Jan 29Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher
Jan 22
We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn
Jan 13Turning Point Therapeutics: An Emerging Growth Story In TKI-Resistant Cancers
Dec 28Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?
Dec 15Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer
Dec 08Turning Point Therapeutics EPS beats by $0.12, beats on revenue
Nov 12Shareholder Returns
| TPTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.3% | -4.2% | -3.7% |
| 1Y | 18.9% | -2.0% | 20.5% |
Return vs Industry: TPTX exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: TPTX exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| TPTX volatility | |
|---|---|
| TPTX Average Weekly Movement | 34.2% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TPTX's share price has been volatile over the past 3 months.
Volatility Over Time: TPTX's weekly volatility has increased from 20% to 34% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 267 | Athena Countouriotis | www.tptherapeutics.com |
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company’s lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors.
Turning Point Therapeutics, Inc. Fundamentals Summary
| TPTX fundamental statistics | |
|---|---|
| Market cap | US$3.81b |
| Earnings (TTM) | -US$342.31m |
| Revenue (TTM) | US$1.01m |
3,776x
P/S Ratio-11.1x
P/E RatioIs TPTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TPTX income statement (TTM) | |
|---|---|
| Revenue | US$1.01m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.01m |
| Other Expenses | US$343.32m |
| Earnings | -US$342.31m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.84 |
| Gross Margin | 100.00% |
| Net Profit Margin | -33,959.03% |
| Debt/Equity Ratio | 0% |
How did TPTX perform over the long term?
See historical performance and comparison